
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 8-K

**Current Report
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934**

November 18, 2014
Date of Report (Date of Earliest Event Reported)

IntelGenx Technologies Corp.
(Exact Name of Registrant as Specified in its Charter)

Delaware
*(State or other jurisdiction of
incorporation)*

000-31187
*(Commission File
Number)*

870638336
*(IRS Employer Identification
No.)*

6425 Abrams, Ville St- Laurent, Quebec, Canada
(Address of principal executive offices)

H4S 1X9
(Zip Code)

Registrant's telephone number, including area code: (514) 331-7440

Check the appropriate box below if the Form 8K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17CFR230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR 240.14a -12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
 - Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
-

Item 8.01 Other Events - News Release

IntelGenx to Present at Singular Research's Best of the Uncovered 2014 NYC Fall Conference

Exhibit	Description
99.1	Press Release

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INTELGENX TECHNOLOGIES CORP.

Dated: November 18, 2014

By: /s/ Paul A. Simmons

Paul A. Simmons
Chief Financial Officer

IntelGenx to Present at Singular Research's Best of the Uncovered 2014 NYC Fall Conference

Saint Laurent, Quebec - November 18, 2014 --IntelGenx Corp. (TSXV: IGX) (OTCQX: IGXT) ("IntelGenx") today announced that Dr. Horst Zerbe, Chairman, President and Chief Executive Officer, will present at the Singular Research Best of the Uncovered 2014 NYC Fall Conference to be held Thursday, November 20, 2014 at the Westin in New York at Times Square. IntelGenx' presentation will take place November 20, 2014 at 12:00 PM Eastern Time.

Institutional investors that wish to request a meeting with IntelGenx should contact the Cockrell Group on 877.889.1972.

A live broadcast of the conference presentation will be available. To access the broadcast, click [here](#) or go to the Company's website at www.intelgenx.com . A replay of the conference presentation will also be available.

About IntelGenx:

IntelGenx is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. IntelGenx uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastrointestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films. IntelGenx' development pipeline includes products for the treatment of indications such as severe depression, hypertension, erectile dysfunction, migraine, insomnia, CNS indications, idiopathic pulmonary fibrosis, oncology and pain, as well as animal health products. More information is available about the company at www.intelgenx.com .

Investor Contact:

COCKRELL GROUP

T: 877.889.1972

investorrelations@thecockrellgroup.com

cockrellgroup.com

Company Contact:

Paul A. Simmons

Chief Financial Officer

IntelGenx Technologies Corp.

T: +1 514-331-7440

F: +1 514-331-0436

www.intelgenx.com
